Omnicell, Inc. Provides Revenue Guidance for Second Quarter and Full Year 2022
April 28, 2022 at 04:01 pm EDT
Share
Omnicell, Inc. provided revenue guidance for second quarter and full year 2022. For the quarter the company expects total GAAP revenues to be between $337 million and $343 million. The Company expects second quarter 2022 GAAP product revenues to be between $241 million and $244 million, and second quarter 2022 GAAP service revenues to be between $96 million and $99 million.
For the year the Company expects product bookings to be between $1.370 billion and $1.430 billion. The Company expects full year 2022 total GAAP revenues to be between $1.385 billion and $1.410 billion. The Company expects full year 2022 GAAP product revenues to be between $975 million and $990 million, and full year 2022 GAAP service revenues to be between $410 million and $420 million.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
OMNICELL, INC. 
